| Literature DB >> 32801665 |
Changwei Liu1, Chee Wei Tham2, Jacqueline De Roza1, Bee Yen Chong3, Yi Ling Koh3, Ngiap Chuan Tan3,4.
Abstract
BACKGROUND: While illness perceptions and medication beliefs have been shown to be associated with inhaled corticosteroid (ICS) adherence in younger adults with asthma, their impact on older adults is less understood. This study aimed to determine the prevalence of ICS adherence among older Asian adults and to assess the association between ICS adherence, illness perceptions and medication beliefs.Entities:
Keywords: asthma; medication adherence; primary healthcare
Year: 2020 PMID: 32801665 PMCID: PMC7414975 DOI: 10.2147/PPA.S266871
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Bivariate Analyses of Participants’ Characteristics and Adherence
| Characteristics | Total n (%) | Poor Adherence* n (%) | Good Adherence** n (%) | |
|---|---|---|---|---|
| 323 (100.0) | 191 (59.1) | 132 (40.9) | – | |
| 60–70 | 165 (51.0) | 101 (61.2) | 64 (38.8) | 0.437 |
| > 70 | 158 (49.0) | 90 (57.0) | 68 (43.0) | |
| Female | 140 (43.0) | 80 (57.1) | 60 (42.9) | 0.524 |
| Male | 183 (57.0) | 111 (60.7) | 72 (39.3) | |
| Chinese | 238 (73.7) | 143 (60.1) | 95 (39.9) | 0.664 |
| Malay | 41 (12.7) | 21 (51.2) | 20 (48.8) | |
| Indian | 40 (12.4) | 24 (60.0) | 16 (40.0) | |
| Eurasian/Others | 4 (1.2) | 3 (75.0) | 1 (25.0) | |
| No formal education/Primary school | 157 (48.8) | 94 (59.9) | 63 (40.1) | 0.758 |
| Secondary school and above | 165 (51.2) | 96 (58.2) | 69 (41.8) | |
| Rental/1/2-room public housing | 61 (18.9) | 35 (57.4) | 26 (42.6) | 0.657 |
| 3/4/5-room/Executive public housing | 216 (66.9) | 126 (58.3) | 90 (41.7) | |
| Private housing | 46 (14.2) | 30 (65.2) | 16 (34.8) | |
| ≤ 40-year-old | 126 (39.1) | 73 (57.9) | 53 (42.1) | 0.726 |
| > 40-year-old | 197 (61.0) | 118 (59.9) | 79 (40.1) | |
| Current smoker | 27 (8.4) | 18 (66.7) | 9 (33.3) | 0.504 |
| Previous smoker | 56 (17.3) | 30 (53.6) | 26 (46.4) | |
| Never smoked before | 240 (74.3) | 143 (60.0) | 97 (40.0) | |
| Yes | 58 (18.0) | 30 (51.7) | 28 (48.3) | 0.205 |
| No | 265 (82.0) | 161 (60.8) | 104 (39.2) | |
| Metered Dose Inhaler | 214 (66.3) | 123 (57.5) | 91 (42.5) | 0.396 |
| Dry Powder Inhaler | 109 (33.7) | 68 (62.4) | 41 (37.6) | |
| ICS monotherapy | 133 (41.2) | 94 (70.7) | 39 (29.3) | <0.001 |
| Combined ICS-LABA therapy | 190 (58.8) | 97 (51.1) | 93 (48.9) | |
| Once a day | 90 (27.9) | 53 (58.9) | 37 (41.1) | 0.956 |
| ≥2 times a day | 233 (72.1) | 138 (59.2) | 95 (40.8) | |
| Step 3 or less | 182 (56.3) | 113 (62.1) | 69 (37.9) | 0.220 |
| Step 4 and above | 141 (43.7) | 78 (55.3) | 63 (44.7) | |
| ACT < 20 | 29 (9.0) | 21 (72.4) | 8 (27.6) | 0.127 |
| ACT ≥ 20 | 294 (91.0) | 170 (57.8) | 124 (42.2) | |
| 0 to 2 | 188 (58.2) | 115 (61.2) | 73 (38.8) | 0.379 |
| > 2 | 135 (41.8) | 76 (56.3) | 59 (43.7) |
Notes: *Poor adherence refers to patients with mean MARS score <4.5. **Good adherence refers to patients with mean MARS score ≥4.5. ∧1 missing data.
Abbreviation: LABA, long acting β-agonists.
Bivariate Analyses of Beliefs and Adherence
| Dimensions | Patients Scoring Above Scale Mid-Point (%) | All, Mean (SD) | Poor Adherence*, Mean (SD) | Good Adherence**, Mean (SD) | |
|---|---|---|---|---|---|
| Consequence | 17.3 | 3.26 (2.45) | 3.45 (2.44) | 2.99 (2.46) | 0.100 |
| Timeline | 64.1 | 6.99 (3.33) | 5.95 (3.43) | 8.50 (2.49) | <0.001 |
| Control | 68.9 | 6.77 (2.53) | 6.28 (2.54) | 7.48 (2.35) | <0.001 |
| Identity | 15.8 | 3.39 (2.25) | 3.58 (2.17) | 3.13 (2.33) | 0.079 |
| Medication-Necessity | 67.5 | 3.43 (0.81) | 3.19 (0.80) | 3.77 (0.71) | <0.001 |
| Medication-Concerns | 30.7 | 2.67 (0.74) | 2.84 (0.73) | 2.44 (0.69) | <0.001 |
Notes: *Poor adherence refers to patients with mean MARS score <4.5. **Good adherence refers to patients with mean MARS score ≥4.5.
Logistic Regression: Factors Influencing ICS Adherence
| Variable | Poor Adherence* | Good Adherence** | Adjusted OR (95% CI) | |
|---|---|---|---|---|
| Consequence | 3.45 (2.44) | 2.99 (2.46) | 0.90 (0.79,1.04) | 0.142 |
| Timeline | 5.95 (3.43) | 8.50 (2.49) | 1.22 (1.10,1.35) | <0.001 |
| Control | 6.28 (2.54) | 7.48 (2.35) | 1.04 (0.92,1.17) | 0.581 |
| Identity | 3.58 (2.17) | 3.13 (2.33) | 0.98 (0.84,1.14) | 0.802 |
| Medication-Necessity | 3.19 (0.80) | 3.77 (0.71) | 2.67 (1.76,4.06) | <0.001 |
| Medication-Concerns | 2.84 (0.73) | 2.44 (0.69) | 0.39 (0.26,0.60) | <0.001 |
| Combined ICS-LABA | 97 (51.1) | 93 (48.9) | 2.50 (1.41,4.44) | 0.02 |
| ICS monotherapy | 94 (70.7) | 39 (29.3) | 1 | - |
Notes: *Poor adherence refers to patients with mean MARS score <4.5. **Good adherence refers to patients with mean MARS score ≥4.5.